JaredMWeissMD

Oncology • Chapel Hill, NC

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Weiss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weiss' full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 984-974-2607

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
Yale School of MedicineClass of 2004

Certifications & Licensure

NC State Medical License 2010 - 2025
PA State Medical License 2007 - 2010
MA State Medical License 2006 - 2009
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2012 Feb 01
Completed
Phase 2
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
Completed
Phase 2
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Start of enrollment: 2012 Jun 01
Active, not recruiting
Phase 2
Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer Start of enrollment: 2012 Jul 01
Completed
Single Arm on the Tolerability of Weekly Nab-paclitaxel Start of enrollment: 2013 Jun 25
Completed
Phase 2
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy Start of enrollment: 2012 Oct 01
Completed
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN Start of enrollment: 2014 Jun 16
Completed
Phase 2
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Start of enrollment: 2014 Jun 09
Completed
Phase 4
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC Start of enrollment: 2015 Jan 01
Terminated
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Start of enrollment: 2024 Apr 05
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study of Trilaciclib and Lurbinectidin Start of enrollment: 2022 Oct 12
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors Start of enrollment: 2023 Jun 26
Recruiting
Roles: Contact
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors Start of enrollment: 2024 May 06
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report.
Shetal A Patel, Young Whang, Chaely Medley, Kevin Chen, Jasmine Jordan
JTO Clinical and Research Reports. 2024-10-01
1 citations
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.
William Tompkins, Connor B Grady, Wei-Ting Hwang, Krishna Chandrasekhara, Caroline McCoach
JTO Clinical and Research Reports. 2024-08-01
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison
Cancer Immunology, Immunotherapy. 2024-03-02

Lectures

Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cis...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Postoperative Chemoradiation: Which Patients, Which Agents?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

Warning on Use of Sotorasib After ICI in Lung CancerJune 1st, 2023
Lung Cancer Symptoms in Non-Smokers Misdiagnosed with COVIDFebruary 14th, 2023
Woman, 39, Had Cough Diagnosed as COVID-19 Pneumonia. It Was Lung CancerMay 18th, 2022
Join now to see all